Corbus Pharmaceuticals

Corbus Pharmaceuticals

MA - Norwood
Pharmaceutical1 H-1B visas (FY2023)

Focus: Orphan inflammatory-fibrotic diseases

Corbus Pharmaceuticals is a life sciences company focused on Orphan inflammatory-fibrotic diseases.

ImmunologyNeurologyRare Diseases
Open Jobs
2

Pipeline & Clinical Trials

Clinical Trials (1)
NCT07310901A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity
Phase 1
Phase 1/2
Clinical Trials (1)
NCT06265727A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors
Phase 1/2
CRB-601 monoclonal antibody
Solid Tumor
Phase 1/2
Clinical Trials (1)
NCT06603844First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.
Phase 1/2
Clinical Trials (1)
NCT02465437Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis
Phase 2
Phase 2
Clinical Trials (1)
NCT02466243Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis
Phase 2
Lenabasum 20 mg
Cystic Fibrosis
Phase 2
Clinical Trials (1)
NCT03451045Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis
Phase 2
Clinical Trials (1)
NCT03093402JBT-101 in Systemic Lupus Erythematosus (SLE)
Phase 2
Phase 2
Clinical Trials (1)
NCT02465450Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 (Lenabasum) in Cystic Fibrosis
Phase 2
Lenabasum 20 mg
Dermatomyositis
Phase 3
Clinical Trials (1)
NCT03813160Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis
Phase 3
Clinical Trials (1)
NCT03398837Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
Phase 3

Open Jobs (2)

Interview Prep Quick Facts
Portfolio: 10 clinical trials
H-1B (2023): 1 approval
Open Roles: 2 active jobs

Hiring Trend

Stable
2
Open Roles
+0
Added
-1
Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas
H-1B Petitions (FY2023)
1
Approved
0
Denied
100%
Rate

Source: USCIS H-1B Employer Data Hub